Supplementary Materials and Methods, Tables S1 through S3 and Figures S1 and S2 from BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

Abstract

<p>Supplementary Materials and Methods, Tables S1 through S3 and Figures S1 and S2 - Supplementary Materials and Methods: The sources, application and dilution of the antibodies used for Western blotting (WB) and immunohistochemical (IHC) analyses in this study are listed. Supplementary Tables: The supplementary tables demonstrate the data and statistics from x-ray co-crystallization experiments with BI 885578 and the human INSR kinase domain (Tables S1 and S2) and the kinase selectivity of BI 885578 on a large panel of human kinases (Table S3). Supplementary Figures: The supplementary figures demonstrate the efficacy and tolerability of BI 885578 in the CL-14 colon cancer xenograft model (Figure S1) and the PD effects of BI 885578 on the phosphorylation of the IGF1R and INSR in GEO tumors (Figure S2).</p>